Analyst: This Penny Stock Could Triple

Euro Pacific Capital thinks upbeat data could snag COCP a large-pharma partner -- or suitor

Jul 17, 2018 at 11:12 AM
facebook twitter linkedin

Biotech stock Cocrystal Pharma Inc (NASDAQ:COCP) is higher this morning, thanks to some bullish attention from analysts. Specifically, Euro Pacific Capital initiated coverage of COCP with a "buy" rating and $14 price target -- representing expected upside of more than 200% to the security's close of $4.34 yesterday. At last check, COCP shares have jumped 4.4% to trade at $4.53.

Digging deeper, the brokerage firm said the market opportunity for hepatitis C infection (HCV) products is "one of the biggest in pharma," and expressed confidence in Cocrystal's management -- in particular, board chairman Dr. Raymond F. Schinazi, co-founder of two pharma companies that were ultimately scooped up by Gilead Sciences (GILD) and Merck (MRK). What's more, Euro Capital thinks positive data "could cause larger pharma to either partner for the development of CC-31244 or to acquire COCP outright."

Cocrystal Pharma stock has already surged 181% since touching a record low of $1.61 in early May. Now, the shares are on pace to retake their 160-day moving average for the first time in 2018. This trendline served as support for COCP in late 2017, and could resume its role as a foothold if today's rally holds.

cocp stock daily price chart on july 17


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners